hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 21:05:27 - browse：76

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Health insurers' Q3 question: how much care are people getting?

focus

WSS

AstraZeneca loses challenge to Medicare drug price negotiation

Congress extends some pandemic preparedness programs

Lawsuit highlights wrinkle for disputes over surprise medical bills

IVG is promising — but it won’t replace IVF quite yet

Covid isolation guidance eased by the CDC

Medical device lobby: We're tired of waiting on Medicare coverage

hotspot

hotspot

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

explore

Duchenne breakthrough therapy leaves behind pioneering families

Change Healthcare cyberattack outage could last weeks

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Malaria cases in Florida and Texas: Here’s what you need to know

Congress extends some pandemic preparedness programs

Virginia high school admissions case could be legal follow

The Karikó problem: Lessons for funding basic research

Trump demands the U.S. pay no more for drugs than other countries … again

Flu vaccine offering decent levels of protection this winter, new data show

focus

Flu vaccine offering decent levels of protection this winter, new data show

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Congress extends some pandemic preparedness programs

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

FDA does about

Scientists unlock the key to scar

leisure time

focus

hotspot

hotspot